[HTML][HTML] The molecular aspects of functional activity of macrophage-activating factor GcMAF

SS Kirikovich, EV Levites, AS Proskurina… - International Journal of …, 2023 - mdpi.com
Group-specific component macrophage-activating factor (GcMAF) is the vitamin D3-binding
protein (DBP) deglycosylated at Thr420. The protein is believed to exhibit a wide range of …

The new general biological property of stem-like tumor cells (Part II: Surface molecules, which belongs to distinctive groups with particular functions, form a unique …

DD Petrova, EV Dolgova, AS Proskurina… - International Journal of …, 2022 - mdpi.com
An ability of poorly differentiated cells of different genesis, including tumor stem-like cells
(TSCs), to internalize extracellular double-stranded DNA (dsDNA) fragments was revealed …

Chronometric administration of cyclophosphamide and a double-stranded DNA-Mix at interstrand crosslinks repair timing, called “Karanahan” therapy, is highly …

V Ruzanova, A Proskurina, Y Efremov… - Pathology and …, 2022 - por-journal.com
Background and Aims: A new technology based on the chronometric administration of
cyclophosphamide and complex composite double-stranded DNA-based compound, which …

[HTML][HTML] Analysis of the biological properties of blood plasma protein with GcMAF functional activity

EV Dolgova, SS Kirikovich, EV Levites… - International Journal of …, 2022 - mdpi.com
The main problem related to the studies focusing on group-specific component protein-
derived macrophage-activating factor (GcMAF) is the lack of clarity about changes occurring …

Antitumor efficacy of multi-target in situ vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamers

AS Proskurina, VS Ruzanova, GS Ritter… - Journal of …, 2022 - pmc.ncbi.nlm.nih.gov
To overcome immune tolerance to cancer, the immune system needs to be exposed to a
multi-target action intervention. Here, we investigated the activating effect of CpG …

Theoretical premises of a “three in one” therapeutic approach to treat immunogenic and nonimmunogenic cancers: a narrative review

AS Proskurina, VS Ruzanova… - Translational …, 2021 - pmc.ncbi.nlm.nih.gov
Objective We describe experimental and theoretical premises of a powerful cancer therapy
based on the combination of three approaches. These include (I) in situ vaccination …

Mesyl phosphoramidate oligonucleotides: a new promising type of antisense agents

DA Stetsenko - Handbook of chemical Biology of nucleic acids, 2023 - Springer
This chapter provides an overview of mesyl phosphoramidate oligonucleotides (μ-
oligonucleotides), which incorporate mesyl phosphoramidate groups (MsPA, or μ) instead of …

[PDF][PDF] Limited Local Clinical Trials for the New Cancer Treatment Technology Karanahan for Patients with Advanced Breast Cancer

VA Markina, AS Proskurina, VS Ruzanova, GS Ritter… - 2024 - preprints.org
(1) Background: Multi-year research into the synergistic effect of cyclophosphamide and
complex composite double-stranded DNA preparation (DNAmix) has made it possible to …